[(18)F]FDG-PET standard uptake value as a metabolic predictor of bone marrow response to radiation: impact on acute and late hematological toxicity in cervical cancer patients treated with chemoradiation therapy

Int J Radiat Oncol Biol Phys. 2014 Dec 1;90(5):1099-107. doi: 10.1016/j.ijrobp.2014.08.017. Epub 2014 Oct 13.

Abstract

Purpose: To quantify the relationship between bone marrow (BM) response to radiation and radiation dose by using (18)F-labeled fluorodeoxyglucose positron emission tomography [(18)F]FDG-PET standard uptake values (SUV) and to correlate these findings with hematological toxicity (HT) in cervical cancer (CC) patients treated with chemoradiation therapy (CRT).

Methods and materials: Seventeen women with a diagnosis of CC were treated with standard doses of CRT. All patients underwent pre- and post-therapy [(18)F]FDG-PET/computed tomography (CT). Hemograms were obtained before and during treatment and 3 months after treatment and at last follow-up. Pelvic bone was autosegmented as total bone marrow (BMTOT). Active bone marrow (BMACT) was contoured based on SUV greater than the mean SUV of BMTOT. The volumes (V) of each region receiving 10, 20, 30, and 40 Gy (V10, V20, V30, and V40, respectively) were calculated. Metabolic volume histograms and voxel SUV map response graphs were created. Relative changes in SUV before and after therapy were calculated by separating SUV voxels into radiation therapy dose ranges of 5 Gy. The relationships among SUV decrease, radiation dose, and HT were investigated using multiple regression models.

Results: Mean relative pre-post-therapy SUV reductions in BMTOT and BMACT were 27% and 38%, respectively. BMACT volume was significantly reduced after treatment (from 651.5 to 231.6 cm(3), respectively; P<.0001). BMACT V30 was significantly correlated with a reduction in BMACT SUV (R(2), 0.14; P<.001). The reduction in BMACT SUV significantly correlated with reduction in white blood cells (WBCs) at 3 months post-treatment (R(2), 0.27; P=.04) and at last follow-up (R(2), 0.25; P=.04). Different dosimetric parameters of BMTOT and BMACT correlated with long-term hematological outcome.

Conclusions: The volumes of BMTOT and BMACT that are exposed to even relatively low doses of radiation are associated with a decrease in WBC counts following CRT. The loss in proliferative BM SUV uptake translates into low WBC nadirs after treatment. These results suggest the potential of intensity modulated radiation therapy to spare BMTOT to reduce long-term hematological toxicity.

MeSH terms

  • Acute Disease
  • Adenocarcinoma / diagnostic imaging
  • Adenocarcinoma / therapy
  • Adult
  • Aged
  • Aged, 80 and over
  • Blood Cell Count
  • Bone Marrow / diagnostic imaging
  • Bone Marrow / metabolism
  • Bone Marrow / radiation effects*
  • Bone Marrow Cells / diagnostic imaging
  • Bone Marrow Cells / metabolism
  • Bone Marrow Cells / radiation effects*
  • Carcinoma, Squamous Cell / diagnostic imaging
  • Carcinoma, Squamous Cell / therapy
  • Chemoradiotherapy / adverse effects
  • Chemoradiotherapy / methods*
  • Cisplatin / administration & dosage
  • Female
  • Fluorodeoxyglucose F18* / pharmacokinetics
  • Humans
  • Middle Aged
  • Multimodal Imaging
  • Positron-Emission Tomography / methods
  • Radiation-Sensitizing Agents / administration & dosage
  • Radiopharmaceuticals* / pharmacokinetics
  • Radiotherapy Dosage
  • Radiotherapy, Intensity-Modulated / methods
  • Regression Analysis
  • Retrospective Studies
  • Tomography, X-Ray Computed / methods
  • Uterine Cervical Neoplasms / diagnostic imaging
  • Uterine Cervical Neoplasms / therapy*

Substances

  • Radiation-Sensitizing Agents
  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18
  • Cisplatin